Alto Neuroscience (NYSE:ANRO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock.

A number of other research analysts also recently commented on ANRO. Robert W. Baird boosted their price objective on shares of Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research report on Wednesday, March 18th. Jefferies Financial Group reissued a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a research note on Monday, March 16th. JonesTrading lowered their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Thursday. Finally, BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Alto Neuroscience Stock Performance

ANRO opened at $21.57 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The company has a market capitalization of $689.03 million, a price-to-earnings ratio of -9.89 and a beta of 2.01. The business has a 50 day moving average price of $19.18 and a two-hundred day moving average price of $14.68. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $25.17.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Research analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the 1st quarter valued at $52,000. Torren Management LLC bought a new position in Alto Neuroscience during the fourth quarter valued at about $62,000. Invesco Ltd. acquired a new stake in shares of Alto Neuroscience in the first quarter worth about $67,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares in the last quarter.

Alto Neuroscience News Roundup

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.